×
GSK Long Term Debt 2010-2024 | GSK
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
GSK long term debt for the quarter ending June 30, 2024 was
$17.136B
, a
12.01% decline
year-over-year.
GSK long term debt for 2023 was
$18.914B
, a
10.24% decline
from 2022.
GSK long term debt for 2022 was
$21.071B
, a
25.52% decline
from 2021.
GSK long term debt for 2021 was
$28.289B
, a
5.95% decline
from 2020.
View More
GSK Long Term Debt 2010-2024 | GSK
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
GSK long term debt for 2023 was
$18.914B
, a
10.24% decline
from 2022.
GSK long term debt for 2022 was
$21.071B
, a
25.52% decline
from 2021.
GSK long term debt for 2021 was
$28.289B
, a
5.95% decline
from 2020.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$180.5B
Regeneron Pharmaceuticals (REGN)
$126.8B
Vertex Pharmaceuticals (VRTX)
$123.3B
Gilead Sciences (GILD)
$104.5B
Bristol Myers Squibb (BMY)
$99.4B
CSL (CSLLY)
$97.5B
Alnylam Pharmaceuticals (ALNY)
$35.5B
Argenex SE (ARGX)
$32.1B
Biogen (BIIB)
$29.3B
BioNTech SE (BNTX)
$26.8B
Moderna (MRNA)
$26.1B
Illumina (ILMN)
$21.4B
BeiGene (BGNE)
$19.3B
Genmab (GMAB)
$17.5B
BioMarin Pharmaceutical (BMRN)
$13.6B
Exact Sciences (EXAS)
$13.1B
Vaxcyte (PCVX)
$13.1B
Insmed (INSM)
$12.9B
Incyte (INCY)
$12.9B
Bio-Techne Corp (TECH)
$12.7B
Sarepta Therapeutics (SRPT)
$12.1B
QIAGEN (QGEN)
$10.4B
Legend Biotech (LEGN)
$9.3B
Bio-Rad Laboratories (BIO.B)
$9.1B
Ascendis Pharma (ASND)
$8.9B
Roivant Sciences (ROIV)
$8.8B
Repligen (RGEN)
$8.2B
Intra-Cellular Therapies (ITCI)
$8.1B
Exelixis (EXEL)
$7.7B
Viking Therapeutics (VKTX)
$7.6B